Updates in intravesical electromotive drug administration® of mitomycin-C for non-muscle invasive bladder cancer

@article{DiStasi2009UpdatesII,
  title={Updates in intravesical electromotive drug administration{\textregistered} of mitomycin-C for non-muscle invasive bladder cancer},
  author={Savino M. Di Stasi and Claus R. Riedl},
  journal={World Journal of Urology},
  year={2009},
  volume={27},
  pages={325-330}
}
Electromotive drug administration® (EMDA) increases the local drug efficacy by controlling and enhancing transmembranous transport into tissue. EMDA of intravesical mitomycin-C (MMC) has been used for treatment of non-muscle invasive bladder cancer (NMIBC) for about a decade on the basis of laboratory studies that demonstrated an enhanced administration rate of MMC into all bladder wall layers after EMDA compared to standard instillation/passive diffusion (PD). Higher MMC concentrations might… 
Intravesical Electro-Osmotic Administration of Mitomycin C
TLDR
Device-assisted intravesical chemotherapy may be a useful ancillary procedure in the treatment of NMIBC and its evaluation must be planned with respect to the technical functioning of equipment and their use for a clear purpose to avoid the financial and human costs associated with incorrect therapies.
The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer
TLDR
Novel intravesical drug delivery systems and how they are addressing challenges in the treatment of NMIBC are discussed, including disease recurrence and progression even with treatment with BCG, as well as issues regarding its availability and patient tolerability.
Single ablative intravesical electromotive mitomycin C administration for small non-muscle-invasive bladder cancer: a prospective study
TLDR
The treatment was well supported, except for two patients who had severe bladder spasms, resulting in early evacuation of the MMC, and a single EMDA-MMC in l papillary bladder tumors <2 cm gives insufficient ablative effect.
Intravesical Treatment with Electro-Mediated Administration of Mytomicin C as Prophylaxis for Intermediate and High-Risk Nonmuscle-Invasive Bladder Cancer: A Retrospective Multicenter Study
TLDR
EMDA was effective in intermediate- and high-risk patients: because of the small number of cases no conclusions can be drawn on the efficacy in the low-risk group, and EMDA/MMC is a useful technique for an effective and safe treatment of primary and recurrent NMIBC.
Second-Line Intravesical Therapy. What is the Present Role of Device-Assisted Therapy?
TLDR
Options for second-line adjuvant therapy for non-muscle-invasive bladder cancer in standard treatment non-responder patients are discussed and device-assisted therapy for the intravesical treatment of bladder cancer, such as thermochemotherapy and electromotive drug administration are investigated.
Chapter 1 Intravesical Treatment Modalities in Bladder Cancer : Current and Future Perspectives
TLDR
In patients with low-risk non–muscle-invasive bladder cancer, posttransurethral resection (TUR) management is a single immediate intravesical instillation of chemotherapy alone, for an intermediate-risk patient, a 6-week course of induction intravesicals chemotherapy or immunotherapy can be adapted.
Current status of the development of intravesical drug delivery systems for the treatment of bladder cancer
TLDR
This review addresses the limitations of conventional therapeutic regimens and reports the use of polymeric hydrogels and nano/microcarriers for enhanced intravesical drug delivery in bladder cancer.
Intravesical Treatment Modalities in Bladder Cancer: Current and Future Perspectives
TLDR
In patients with low-risk non–muscle-invasive bladder cancer, posttransurethral resection (TUR) management is a single immediate intravesical instillation of chemotherapy alone, for an intermediate-risk patient, a 6-week course of induction intravesicals chemotherapy or immunotherapy can be adapted.
Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer
TLDR
The long-term impact of intravesical BCG, mitomycin, epirubicin, and transurethral resection alone demonstrated marginal impact on recurrence, however, BCG with or without maintenance appeared to reduce disease progression over the long term compared to other therapies.
...
...

References

SHOWING 1-10 OF 34 REFERENCES
Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients.
TLDR
Intravesical exposure to MMC showed large intra- and intersubject variabilities, as determined by the area under the urine concentration-time curve, and the superficial bladder tissue was exposed to drug concentrations 300- to greater than 34,000-fold higher than the plasma-perfused systemic tissues.
Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
TLDR
Intravesical electromotive administration increases bladder uptake of MMC, resulting in an improved response rate in cases of high risk superficial bladder cancer.
Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.
TLDR
Improvements were found in all risk groups defined by tumor stage, grade, focality, and recurrence, which identified a pharmacologically optimized intravesical mitomycin C treatment with statistically significantly enhanced efficacy.
Electromotive delivery of mitomycin C into human bladder wall.
TLDR
In conclusion, EMDA enhances administration of MMC into viable bladder wall tissue and reduces the variability in drug delivery rates.
Bladder wall penetration of intravesical mitomycin C in dogs.
TLDR
The kinetics of penetration of mitomycin C in the dog bladder wall after intravesical instillation of 20 mg/40 ml, a dose used in patients, supports the therapeutic advantage of intravesicals therapy of high local drug concentrations while minimizing systemic exposure.
Penetration of mitomycin C in human bladder.
TLDR
The penetration of mitomycin C (MMC) in bladder tissue was studied in patients who received intravesical chemotherapy at the time of radical cystectomy and the rate of concentration declined with respect to tissue depth and hence the distance over which the MMC concentration decreased by one-half was similar in both tumors.
Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer
TLDR
It is hypothesize that the increase in tissue exposure in the optimized treatment would result in a 20% improvement over the standard therapy along with an increase in the recurrence-free rate from 56% to 76% of patients.
Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies.
TLDR
It was concluded that EMDA significantly enhances MMC transport into all of the layers of the bladder wall, and sections of viable human bladder are a reliable tool for assessing different modes of drug delivery.
...
...